Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2021

09.07.2020 | Thoracic Oncology

Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival

verfasst von: Matthew Parsons, MD, Shane Lloyd, MD, Skyler Johnson, MD, Courtney Scaife, MD, Thomas Varghese, MD, MS, Robert Glasgow, MD, Ignacio Garrido-Laguna, MD, PhD, Randa Tao, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to understand factors associated with refusal of local therapy in esophageal cancer and compare the overall survival (OS) of patients who refuse therapies with those who undergo recommended treatment.

Methods

National Cancer Database data for patients with non-metastatic esophageal cancer from 2006 to 2013 were pooled. T1N0M0 tumors were excluded. Pearson’s Chi-square test and multivariate logistic regression analyses were used to assess demographic, clinical, and treatment factors. After propensity-score matching with inverse probability of treatment weighting, OS was compared between patients who refused therapies and those who underwent recommended therapy, using Kaplan–Meier analyses and doubly robust estimation with multivariate Cox proportional hazards modeling.

Results

In total, 37,618 patients were recommended radiation therapy (RT) and/or esophagectomy; we found 1403 (3.7%) refused local therapies. Specifically, 890 of 18,942 (4.6%) patients refused surgery and 667 of 31,937 (2.1%) refused RT. Older patients, females, those with unknown lymphovascular space invasion, and those uninsured or on Medicare were more likely to refuse. Those with squamous cell carcinoma, N1 disease, higher incomes, living farther from care, and those who received chemotherapy were less likely to refuse. Five-year OS was decreased in patients who refused (18.1% vs. 27.6%). The survival decrement was present in adenocarcinoma but not squamous cell carcinoma. In patients who received surgery or ≥ 50.4 Gy RT, there was no OS decrement to refusing the other therapy.

Conclusions

We identified characteristics that correlate with refusal of local therapy. Refusal of therapy was associated with decreased OS. Patients who received either surgery or ≥ 50.4 Gy RT had no survival decrement from refusing the opposite modality.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–8.PubMedCrossRef Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–8.PubMedCrossRef
3.
Zurück zum Zitat Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25(24):3719–25.PubMedCrossRef Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25(24):3719–25.PubMedCrossRef
4.
Zurück zum Zitat Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.PubMedCrossRef Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.PubMedCrossRef
5.
Zurück zum Zitat Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.PubMedPubMedCentralCrossRef Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.PubMedCrossRef van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.PubMedCrossRef
7.
Zurück zum Zitat Dhungel B, Diggs BS, Hunter JG, Sheppard BC, Vetto JT, Dolan JP. Patient and peri-operative predictors of morbidity and mortality after esophagectomy: American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP), 2005–2008. J Gastrointest Surg. 2010;14(10):1492–501.PubMedCrossRef Dhungel B, Diggs BS, Hunter JG, Sheppard BC, Vetto JT, Dolan JP. Patient and peri-operative predictors of morbidity and mortality after esophagectomy: American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP), 2005–2008. J Gastrointest Surg. 2010;14(10):1492–501.PubMedCrossRef
8.
Zurück zum Zitat Raymond DP, Seder CW, Wright CD, et al. Predictors of major morbidity or mortality after resection for esophageal cancer: a society of thoracic surgeons general thoracic surgery database risk adjustment model. Ann Thorac Surg. 2016;102(1):207–14.PubMedPubMedCentralCrossRef Raymond DP, Seder CW, Wright CD, et al. Predictors of major morbidity or mortality after resection for esophageal cancer: a society of thoracic surgeons general thoracic surgery database risk adjustment model. Ann Thorac Surg. 2016;102(1):207–14.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Moskovitz AH, Rizk NP, Venkatraman E, et al. Mortality increases for octogenarians undergoing esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2006;82(6):2031–6. discussion 2036.PubMedCrossRef Moskovitz AH, Rizk NP, Venkatraman E, et al. Mortality increases for octogenarians undergoing esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2006;82(6):2031–6. discussion 2036.PubMedCrossRef
11.
Zurück zum Zitat Derogar M, Lagergren P. Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study. J Clin Oncol. 2012;30(4):413–8.PubMedCrossRef Derogar M, Lagergren P. Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study. J Clin Oncol. 2012;30(4):413–8.PubMedCrossRef
12.
Zurück zum Zitat Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.PubMedCrossRef Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.PubMedCrossRef
13.
Zurück zum Zitat Suntharalingam M, Winter K, Ilson D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 Phase 3 randomized clinical trial. JAMA Oncol. 2017;3(11):1520–8.PubMedPubMedCentralCrossRef Suntharalingam M, Winter K, Ilson D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 Phase 3 randomized clinical trial. JAMA Oncol. 2017;3(11):1520–8.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Kawamoto T, Shikama N, Oshima M, Kosugi Y, Tsurumaru M, Sasai K. Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer. J Geriatr Oncol. 2020;11(4):675–9.PubMedCrossRef Kawamoto T, Shikama N, Oshima M, Kosugi Y, Tsurumaru M, Sasai K. Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer. J Geriatr Oncol. 2020;11(4):675–9.PubMedCrossRef
15.
Zurück zum Zitat Shao MS, Wong AT, Schwartz D, Weiner JP, Schreiber D. Definitive or preoperative chemoradiation therapy for esophageal cancer: patterns of care and survival outcomes. Ann Thorac Surg. 2016;101(6):2148–2154.PubMedCrossRef Shao MS, Wong AT, Schwartz D, Weiner JP, Schreiber D. Definitive or preoperative chemoradiation therapy for esophageal cancer: patterns of care and survival outcomes. Ann Thorac Surg. 2016;101(6):2148–2154.PubMedCrossRef
16.
Zurück zum Zitat Kamel MK, Lee B, Rahouma M, et al. T1N0 oesophageal cancer: patterns of care and outcomes over 25 years. Eur J Cardiothorac Surg. 2018;53(5):952–9.PubMedCrossRef Kamel MK, Lee B, Rahouma M, et al. T1N0 oesophageal cancer: patterns of care and outcomes over 25 years. Eur J Cardiothorac Surg. 2018;53(5):952–9.PubMedCrossRef
17.
Zurück zum Zitat Rahouma M, Harrison S, Kamel M, et al. Consequences of refusing surgery for esophageal cancer: a national cancer database analysis. Ann Thorac Surg. 2018;106(5):1476–83.PubMedCrossRef Rahouma M, Harrison S, Kamel M, et al. Consequences of refusing surgery for esophageal cancer: a national cancer database analysis. Ann Thorac Surg. 2018;106(5):1476–83.PubMedCrossRef
18.
Zurück zum Zitat Murphy CC, Correa AM, Ajani JA, et al. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013;17(8):1359–69.PubMedPubMedCentralCrossRef Murphy CC, Correa AM, Ajani JA, et al. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013;17(8):1359–69.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Noordman BJ, Verdam MGE, Lagarde SM, et al. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Ann Oncol. 2018;29(2):445–51.PubMedCrossRef Noordman BJ, Verdam MGE, Lagarde SM, et al. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Ann Oncol. 2018;29(2):445–51.PubMedCrossRef
20.
Zurück zum Zitat Depypere L, Thomas M, Moons J, et al. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. World J Surg Oncol. 2019;17(1):89.PubMedPubMedCentralCrossRef Depypere L, Thomas M, Moons J, et al. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. World J Surg Oncol. 2019;17(1):89.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90.PubMedPubMedCentralCrossRef Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Ohri N, Rapkin BD, Guha D, et al. Predictors of radiation therapy noncompliance in an urban academic cancer center. Int J Radiat Oncol Biol Phys. 2015;91(1):232–8.PubMedCrossRef Ohri N, Rapkin BD, Guha D, et al. Predictors of radiation therapy noncompliance in an urban academic cancer center. Int J Radiat Oncol Biol Phys. 2015;91(1):232–8.PubMedCrossRef
23.
Zurück zum Zitat Ohri N, Rapkin BD, Guha C, Kalnicki S, Garg M. Radiation therapy noncompliance and clinical outcomes in an urban academic cancer center. Int J Radiat Oncol Biol Phys. 2016;95(2):563–70.PubMedCrossRef Ohri N, Rapkin BD, Guha C, Kalnicki S, Garg M. Radiation therapy noncompliance and clinical outcomes in an urban academic cancer center. Int J Radiat Oncol Biol Phys. 2016;95(2):563–70.PubMedCrossRef
24.
Zurück zum Zitat Arrossi S, Matos E, Zengarini N, Roth B, Sankaranayananan R, Parkin M. The socio-economic impact of cervical cancer on patients and their families in Argentina, and its influence on radiotherapy compliance. Results from a cross-sectional study. Gynecol Oncol. 2007;105(2):335–40.PubMedCrossRef Arrossi S, Matos E, Zengarini N, Roth B, Sankaranayananan R, Parkin M. The socio-economic impact of cervical cancer on patients and their families in Argentina, and its influence on radiotherapy compliance. Results from a cross-sectional study. Gynecol Oncol. 2007;105(2):335–40.PubMedCrossRef
25.
26.
Zurück zum Zitat Rapp J, Tuminello S, Alpert N, Flores RM, Taioli E. Disparities in surgery for early-stage cancer: the impact of refusal. Cancer Causes Control. 2019;30(12):1389–97.PubMedCrossRef Rapp J, Tuminello S, Alpert N, Flores RM, Taioli E. Disparities in surgery for early-stage cancer: the impact of refusal. Cancer Causes Control. 2019;30(12):1389–97.PubMedCrossRef
27.
Zurück zum Zitat Coffman A, Torgeson A, Lloyd S. Correlates of refusal of surgery in the treatment of non-metastatic pancreatic adenocarcinoma. Ann Surg Oncol. 2019;26(1):98–108.PubMedCrossRef Coffman A, Torgeson A, Lloyd S. Correlates of refusal of surgery in the treatment of non-metastatic pancreatic adenocarcinoma. Ann Surg Oncol. 2019;26(1):98–108.PubMedCrossRef
28.
Zurück zum Zitat Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74.PubMedCrossRef Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74.PubMedCrossRef
29.
Zurück zum Zitat Hulshof MCCM, Geijsen D, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, et al. A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study. J Clin Oncol 2020;38(4 Suppl):281.CrossRef Hulshof MCCM, Geijsen D, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, et al. A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study. J Clin Oncol 2020;38(4 Suppl):281.CrossRef
31.
Zurück zum Zitat Xu Y, Zhu W, Zheng X, et al. A multi-center, randomized, prospective study evaluating the optimal radiation dose of definitive concurrent chemoradiation for inoperable esophageal squamous cell carcinoma. J Clin Oncol. 2018;36(15 Suppl):4013.CrossRef Xu Y, Zhu W, Zheng X, et al. A multi-center, randomized, prospective study evaluating the optimal radiation dose of definitive concurrent chemoradiation for inoperable esophageal squamous cell carcinoma. J Clin Oncol. 2018;36(15 Suppl):4013.CrossRef
32.
Zurück zum Zitat Li C, Ni W, Wang X, et al. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal cancer. Radiat Oncol. 2019;14(1):48.PubMedPubMedCentralCrossRef Li C, Ni W, Wang X, et al. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal cancer. Radiat Oncol. 2019;14(1):48.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Chen D, Menon H, Verma V, et al. Results of a phase 1/2 trial of chemoradiotherapy with simultaneous integrated boost of radiotherapy dose in unresectable locally advanced esophageal cancer. JAMA Oncol. 2019;5(11):1597–604.PubMedCentralCrossRef Chen D, Menon H, Verma V, et al. Results of a phase 1/2 trial of chemoradiotherapy with simultaneous integrated boost of radiotherapy dose in unresectable locally advanced esophageal cancer. JAMA Oncol. 2019;5(11):1597–604.PubMedCentralCrossRef
34.
Zurück zum Zitat Venkat PS, Shridhar R, Naghavi AO, et al. Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer. Dis Esophagus. 2017;30(7):1–9.PubMedCrossRef Venkat PS, Shridhar R, Naghavi AO, et al. Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer. Dis Esophagus. 2017;30(7):1–9.PubMedCrossRef
35.
Zurück zum Zitat Welsh JW, Seyedin SN, Allen PK, et al. Local control and toxicity of a simultaneous integrated boost for dose escalation in locally advanced esophageal cancer: interim results from a prospective phase I/II trial. J Thorac Oncol. 2017;12(2):375–82.PubMedCrossRef Welsh JW, Seyedin SN, Allen PK, et al. Local control and toxicity of a simultaneous integrated boost for dose escalation in locally advanced esophageal cancer: interim results from a prospective phase I/II trial. J Thorac Oncol. 2017;12(2):375–82.PubMedCrossRef
36.
Zurück zum Zitat Funk MJ, Westreich D, Wiesen C, Sturmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. Am J Epidemiol 2011;173(7):761–7.PubMedPubMedCentralCrossRef Funk MJ, Westreich D, Wiesen C, Sturmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. Am J Epidemiol 2011;173(7):761–7.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399–424.CrossRef Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399–424.CrossRef
Metadaten
Titel
Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival
verfasst von
Matthew Parsons, MD
Shane Lloyd, MD
Skyler Johnson, MD
Courtney Scaife, MD
Thomas Varghese, MD, MS
Robert Glasgow, MD
Ignacio Garrido-Laguna, MD, PhD
Randa Tao, MD
Publikationsdatum
09.07.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08761-7

Weitere Artikel der Ausgabe 2/2021

Annals of Surgical Oncology 2/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.